8-K: Roivant's Brepocitinib Shines in Phase 3 Dermatomyositis Trial

Roivant Sciences Ltd. announced positive Phase 3 VALOR study results for brepocitinib in dermatomyositis, demonstrating significant clinical improvement and a consistent safety profile.

Summary

• Brepocitinib 30 mg achieved a week 52 mean Total Improvement Score (TIS) of 46.5 compared to 31.2 for placebo (p=0.0006).
• Demonstrated clinically meaningful and statistically significant improvement on all nine key secondary endpoints, including measurements of skin disease (CDASI), muscle disease (MMT-8), steroid-sparing effect, and rapidity of onset.
• 62% of brepocitinib 30 mg patients on background steroids achieved a steroid dose ≤2.5 mg/day by week 52, compared to 34% for placebo.
• 42% of brepocitinib 30 mg patients were able to come off steroids altogether, compared to 23% for placebo.
• Onset of action was rapid, with statistically significant separation from placebo on TIS and CDASI-A as early as week 4.
• Safety profile was consistent with previous clinical trials of brepocitinib.
• Priovant plans to file an NDA for brepocitinib in dermatomyositis in the first half of 2026.

Sentiment

Score: 9

Explanation: The filing reports highly positive Phase 3 clinical trial results for brepocitinib in dermatomyositis, meeting all primary and key secondary endpoints with statistical significance and a consistent safety profile. This represents a landmark achievement in a disease with high unmet medical need and a history of failed therapies, positioning the company for an NDA filing in 1H 2026.

Positives

• Brepocitinib 30 mg achieved statistically significant and clinically meaningful improvement on the primary endpoint (TIS of 46.5 vs. 31.2 for placebo, p=0.0006).
• All nine key secondary endpoints, including skin disease (CDASI), muscle disease (MMT-8), and steroid-sparing, showed significant improvement.
• Over two-thirds (68%) of brepocitinib 30 mg patients experienced at least a moderate response (TIS40), and nearly half (46%) experienced a major response (TIS60).
• Significant steroid reduction: 62% of brepocitinib 30 mg patients on background steroids reduced their dose to ≤2.5 mg/day, and 42% came off steroids entirely.
• Rapid onset of action, with statistically significant separation from placebo on TIS and CDASI-A as early as week 4.
• Safety profile was consistent with previous brepocitinib clinical trials, with adverse events of special interest balanced across treatment arms.
• Represents the first ever positive outcome for a 52-week placebo-controlled trial in dermatomyositis and the first positive registrational trial for a targeted therapy in DM.

Risks

• Actual results may differ materially from forward-looking statements due to various risks, uncertainties, and other factors.
• The company operates in a very competitive and rapidly changing environment where new risks emerge.
• Risks are set forth in the Risk Factors section of SEC filings.
• Timing of litigation-related events is subject to change, including at the discretion of the court.
• Differences exist between study or trial designs and subject characteristics, and caution should be exercised when comparing data across studies (cross-trial comparison disclaimer).

Future Outlook

Priovant plans to file a New Drug Application (NDA) for brepocitinib in dermatomyositis in the first half of 2026. Roivant anticipates further registrational data readouts and potential product launches for other pipeline assets, including IMVT-1402 in multiple indications and batoclimab in Thyroid Eye Disease (TED) in 2H 2025. The company is also advancing LNP litigation with Moderna and Pfizer/BioNTech.

Management Comments

• "The VALOR study's success represents a groundbreaking moment for the dermatomyositis field, and the results reinforce brepocitinib's potential to serve as a deeply impactful treatment option for a substantial number of dermatomyositis patients once approved." Dr. Ruth Ann Vleugels, Harvard Medical School.
• "We are thrilled with the results of the VALOR study, and I would like to thank all of the patients, investigators, and study site staff who contributed to this important research achievement. We are excited to continue working towards the rapid approval of brepocitinib in dermatomyositis and our broader goal of developing brepocitinib as a transformational therapy for multiple highly morbid autoimmune diseases where the need for novel efficacious therapies is greatest." Ben Zimmer, Priovant CEO.
• "The VALOR study is a hallmark example of what Roivant does best: identify a high value program with a differentiated mechanism of action, focus on creative development plans in indications like DM with high unmet need, and deliver on clinical execution excellence. I am extremely proud of Roivant's continued track record with VALOR as the 12th consecutive positive Phase 3 study for the company – an unparalleled achievement and a testament to Roivant's unrelenting focus on clinical strategy and execution." Mayukh Sukhatme, Roivant President and Chief Investment Officer.

Industry Context

Dermatomyositis (DM) is a debilitating autoimmune disease affecting approximately 50,000 adults in the U.S., characterized by muscle weakness and disfiguring skin lesions. There are currently no targeted therapies approved for DM, and standard-of-care largely relies on corticosteroids and off-label immunosuppressive therapies, which often involve chronic high-dose steroid use. Brepocitinib's success marks the first positive outcome for a 52-week placebo-controlled trial and the first positive registrational trial for a targeted therapy in DM, addressing a significant unmet medical need in a field with a long track record of failed targeted therapies.

Comparison to Industry Standards

• Brepocitinib is the first successful registrational trial for a targeted therapy in dermatomyositis (DM).
• It is the first successful 52-week placebo-controlled trial for any therapy in DM.
• It is the first successful placebo-controlled trial of any kind for a once-daily oral therapy in DM.
• The VALOR study was the largest interventional DM trial ever conducted, including other ongoing trials.
• Cross-trial comparison to Octagam (IVIg) in the ProDERM study (Week 40, open-label) showed brepocitinib 30 mg (VALOR, Week 52, placebo-controlled) achieved a TIS40 response rate of 68% compared to Octagam's 58%, and a TIS60 response rate of 46% compared to Octagam's 38%.
• Other targeted therapies, including blockbusters in other I&I indications (e.g., Rituxan, Enbrel, Remicade, Humira, Xeljanz, Orencia, Actemra), have failed in DM and/or polymyositis (PM) or immune-mediated necrotizing myopathy (IMNM).

Legal Proceedings

• Summary judgment phase ongoing in US Moderna LNP litigation case.
• Jury trial scheduled for March 2026 for US Moderna LNP litigation case.
• Ongoing progress following Markman ruling in Pfizer/BioNTech LNP litigation case.

Related Party Transactions

• Roivant owns 74% of Priovant (65% on a fully diluted basis as of June 30, 2025), with Pfizer owning 25%.
• Priovant is obligated to pay Pfizer mid tens-of-millions if sales exceed a mid hundreds-of-millions amount in Priovant territories.
• Pfizer is obligated to pay Priovant low tens-of-millions if sales exceed a mid hundreds-of-millions amount in non-Priovant territories.
• Priovant is obligated to pay Pfizer tiered sub-teens royalties on annual sales in Priovant territories.
• Pfizer is obligated to pay Priovant tiered high single digits to sub-teens royalties on annual sales in non-Priovant territories.

Stakeholder Impact

• Patients: Potential for a novel, efficacious, once-daily oral treatment for dermatomyositis, a debilitating autoimmune disease with high unmet medical need, offering significant improvement in muscle and skin symptoms and steroid reduction.
• Shareholders: Positive clinical trial results for a key pipeline asset (brepocitinib) de-risk the development pathway and enhance the company's valuation, potentially leading to increased share price.
• Investment Professionals: Provides strong data for investment decisions, highlighting Roivant's clinical execution capabilities and pipeline strength.
• Regulatory Authorities: The positive Phase 3 data supports a planned NDA submission, indicating a potential new approved therapy for dermatomyositis.

Next Steps

• Priovant plans to file a New Drug Application (NDA) for brepocitinib in dermatomyositis in the first half of 2026.
• Roivant will host an investor call to discuss these updates on September 17, 2025.
• Upcoming Roivant Investor Day on Thursday, December 11, 2025.
• Continue advancing LNP litigation with Moderna and Pfizer/BioNTech.
• Continue active enrollment for brepocitinib in non-infectious uveitis and cutaneous sarcoidosis.
• Continue active enrollment for IMVT-1402 in Graves Disease, Difficult-to-Treat Rheumatoid Arthritis, Myasthenia Gravis, Sjogren's Disease, Chronic Inflammatory Demyelinating Polyneuropathy, and Cutaneous Lupus Erythematosus.
• Expect topline data for batoclimab in Thyroid Eye Disease (TED) in 2H 2025.
• Continue active enrollment for mosliciguat in Pulmonary Hypertension associated with Interstitial Lung Disease.

Key Dates

Recommendation

The positive Phase 3 VALOR study results for brepocitinib in dermatomyositis are a significant de-risking event for Roivant. Achieving statistical significance on the primary and all key secondary endpoints, coupled with a favorable safety profile and a planned NDA filing in 1H 2026, positions brepocitinib as a potential first-in-class targeted oral therapy for a disease with high unmet medical need and a history of clinical trial failures. This success validates Roivant's development strategy and enhances the value of its pipeline, making it a compelling 'strong buy' for investors seeking exposure to a company with strong clinical execution and significant market potential in autoimmune diseases.

Keywords

Dermatomyositis, brepocitinib, Phase 3, VALOR study, autoimmune disease, TYK2/JAK1 inhibitor, Priovant Therapeutics, Roivant Sciences, clinical trial results, NDA filing, targeted therapy, TIS, CDASI, muscle weakness, skin lesions